TEL AVIV - SciSparc Ltd. (NASDAQ:SPRC), a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, announced today that the Canadian Intellectual Property Office has granted the company a patent for its core technology. This technology combines cannabinoids with n-acylethanolamines to enhance the safety and therapeutic effects of cannabinoids at lower dosages.
The newly granted patent is a significant addition to SciSparc's intellectual property portfolio, supporting the advancement of the company's proprietary technologies. The patent specifically covers the compositions and methods for boosting therapeutic effects and minimizing side effects of cannabinoids, substances originally found in the cannabis plant.
Oz Adler, CEO of SciSparc, stated, "With this patent, we continue to strengthen our global intellectual property rights." He emphasized the company's commitment to developing technologies for treating central nervous system disorders, which he believes adds value for SciSparc investors.
SciSparc's drug development programs include treatments for Tourette Syndrome, Alzheimer's disease, pain, ASD, and status epilepticus, utilizing THC and non-psychoactive CBD. The company also holds a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon.com (NASDAQ:AMZN).
The information provided in this article is based on a press release statement from SciSparc Ltd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.